Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PTC Therapeutics, Inc., Xencor or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how PTC Therapeutics, Inc., Xencor and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About PTC Therapeutics, Inc., Xencor and Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn’s disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Latest Biotechnology and PTC Therapeutics, Inc., Xencor, Inc. Stock News

As of August 26, 2026, PTC Therapeutics, Inc. had a $6.1 billion market capitalization, compared to the Biotechnology median of $298.4 million. PTC Therapeutics, Inc.’s stock is down 5.5% in 2026, up 1.8% in the previous five trading days and up 47.44% in the past year.

Currently, PTC Therapeutics, Inc. does not have a price-earnings ratio. PTC Therapeutics, Inc.’s trailing 12-month revenue is $1.0 billion with a -3.8% net profit margin. Year-over-year quarterly sales growth most recently was 101.5%. Analysts expect adjusted earnings to reach $1.597 per share for the current fiscal year. PTC Therapeutics, Inc. does not currently pay a dividend.

As of August 26, 2026, Xencor, Inc. had a $2.1 billion market cap, putting it in the 54th percentile of all stocks. Xencor, Inc.’s stock is up 88.6% in 2026, up 7% in the previous five trading days and up 255.06% in the past year.

Currently, Xencor, Inc. does not have a price-earnings ratio. Xencor, Inc.’s trailing 12-month revenue is $105.0 million with a -155.6% net profit margin. Year-over-year quarterly sales growth most recently was 17.4%. Analysts expect adjusted earnings to reach $-3.114 per share for the current fiscal year. Xencor, Inc. does not currently pay a dividend.

How We Compare PTC Therapeutics, Inc., Xencor and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PTC Therapeutics, Inc., Xencor and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

PTC Therapeutics, Inc., Xencor and Inc. Stock Value Grades

Company	Ticker	Value
PTC Therapeutics, Inc.	PTCT	F
Xencor, Inc.	XNCR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

PTC Therapeutics, Inc. has a Value Score of 8, which is Ultra Expensive. Xencor, Inc. has a Value Score of 11, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Xencor or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Xencor or Inc. is the better investment when it comes to value.

PTC Therapeutics, Inc., Xencor and Inc. Growth Grades

Company	Ticker	Growth
PTC Therapeutics, Inc.	PTCT	F
Xencor, Inc.	XNCR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

PTC Therapeutics, Inc. has a Growth Score of 20, which is Very Weak. Xencor, Inc. has a Growth Score of 9, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Xencor or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Xencor or Inc. is the better investment when it comes to sustainable growth.

PTC Therapeutics, Inc., Xencor and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
PTC Therapeutics, Inc.	PTCT	B
Xencor, Inc.	XNCR	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

PTC Therapeutics, Inc. has a Earnings Estimate Score of 72, which is Positive. Xencor, Inc. has a Earnings Estimate Score of 67, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both PTC Therapeutics, Inc., Xencor and Inc. have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether PTC Therapeutics, Inc., Xencor or Inc. is a better fit.

Other PTC Therapeutics, Inc., Xencor and Inc. Grades

In addition to Growth, Estimate Revisions and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether PTC Therapeutics, Inc., Xencor and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, PTC Therapeutics, Inc., Xencor or Inc. Stock?

Overall, PTC Therapeutics, Inc. stock has a Value Score of 8, Growth Score of 20 and Estimate Revisions Score of 72.

Xencor, Inc. stock has a Value Score of 11, Growth Score of 9 and Estimate Revisions Score of 67.

Comparing PTC Therapeutics, Inc., Xencor and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.